Pathway related to bone cancer pain identified in animal study | Drug candidates studied for migraine prevention | Studies show promise of virtual reality in pain treatment
June 14, 2017
News for the pain professional
Pain Research News
Pathway related to bone cancer pain identified in animal study
Modulating sphingosine 1-phosphate receptor subtype 1 decreased bone pain and neuroinflammation in an animal model of metastasized breast cancer in the femur, according to a study in the journal Pain. "Pain is a huge problem -- for the patient, the caregiver, the family, the doctors. We have limited options," said researcher Daniela Salvemini of Saint Louis University.
Medical Xpress (6/7) 
LinkedIn Twitter Facebook Google+ Email
Other News
Treatment News
Researchers report pain studies at neuromodulation conference
Patients with a neuromodulation device implant to reduce lower-back and leg pain may prefer leads that interact over those that act independently, according to research presented at the International Neuromodulation Society's World Congress. A second study presented at the conference found high-frequency spinal cord stimulation may help treat peripheral polyneuropathy.
Medscape (free registration)/Reuters (6/9),  Medscape (free registration)/Reuters (6/12) 
LinkedIn Twitter Facebook Google+ Email
Study: Bright-light therapy may reduce fibromyalgia symptoms
A study presented at a sleep conference found using morning bright-light treatment as an adjunctive treatment for fibromyalgia may help reduce pain sensitivity and improve function. Researchers found improvement gained from morning bright-light therapy was similar to that from cognitive-behavioral therapy and about half of what is gained from intense exercise therapy.
Medscape (free registration) (6/13) 
LinkedIn Twitter Facebook Google+ Email
Policy & Trends
Gottlieb: FDA to take "more forceful" action on opioid crisis
FDA Commissioner Scott Gottlieb said the agency will take "more forceful steps" to stem opioid addiction, including creating a steering committee to look at additional regulatory and policy responses. The public will be able to participate in online forums and a two-day meeting set for July 10 and 11.
Medscape (free registration) (6/13) 
LinkedIn Twitter Facebook Google+ Email
FDA requests withdrawal of painkiller amid escalated response to opioid crisis
FDA orders market withdrawal of Endo painkiller amid opioid crisis
(Luis Robayo/AFP/Getty Images)
The FDA has asked Endo International to withdraw its long-lasting opioid painkiller, Opana ER, from the market as the agency escalates its efforts to fight the worsening opioid abuse crisis in the country. The decision, based on indicators that a version reformulated for abuse deterrence is simply being injected rather than abused via nasal administration, marks the first time that the FDA has taken such steps to address a public health crisis.
Reuters (6/8),  The Washington Post (tiered subscription model) (6/8) 
LinkedIn Twitter Facebook Google+ Email
APS News
SmartBrief Terms of Use and Privacy Policy
We are updating our Terms of Use and Privacy Policy and we want to share the details with you.

Effective May 18, 2017, updates will go into effect for SmartBrief's Terms of Use and Privacy Policy. You may view the updated documents by selecting the following links.
For your convenience, the following is a summary of the important changes. We recommend reviewing each document fully.

Terms of Use
  • Allows us to notify you of changes to our Terms of Use by posting a notice on our website.
  • Updates the license you grant us to use content that you provide to us.
Privacy Policy
  • Updates to address how we share information with our social media partners and other service providers.
  • Includes information for California residents on their state privacy rights.
LinkedIn Twitter Facebook Google+ Email
Good order is the foundation of all good things.
Edmund Burke,
statesman and orator
LinkedIn Twitter Facebook Google+ Email
Learn more about APS:
Membership | Annual Meeting | Education
Funding Opportunities | About Us
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Lauren Barr
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information